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SUMMARY
The Drugs for Neglected Diseases initiative (DNDi) has deﬁned and implemented an early discovery strategy over the last
few years, in ﬁtting with its virtual R&D business model. This strategy relies on a medium- to high-throughput phenotypic
assay platform to expedite the screening of compound libraries accessed through its collaborations with partners from the
pharmaceutical industry. We review the pragmatic approaches used to select compound libraries for screening against
kinetoplastids, taking into account screening capacity. The advantages, limitations and current achievements in identifying
new quality series for further development into preclinical candidates are critically discussed, together with attractive new
approaches currently under investigation.
Key words: High-throughput, high-content, screening, DNDi, library selection, human African trypanosomiasis,
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INTRODUCTION
The Drugs for Neglected Diseases initiative
(DNDi) is a patients’ needs-driven product develop-
ment partnership created in 2003 which aims to
address the lack of eﬃcacious and safe treatments
for neglected diseases. DNDi has adopted a prag-
matic virtual R&D model operating in collaboration
with partners from pharmaceutical as well as non-
pharmaceutical sectors. The organization has a
portfolio of research and development projects span-
ning the kinetoplastid infections (human African
trypansomiasis, leishmaniasis and Chagas’ disease),
paediatric HIV infection, malaria and the ﬁlarial
infections, onchocerciasis and lymphatic ﬁlariasis
(www.dndi.org/diseases-projects/portfolio.html). At
the research stage, DNDi concentrates its eﬀorts
on the establishment of a healthy and diverse pipeline
for the ﬁlarial infections, human African trypano-
somiasis, visceral leishmaniasis and Chagas’ diseases,
bearing in mind the inevitable attrition rate related to
any R&D programme (Ioset and Chang, 2011). This
article will focus on strategies related to the screening
of chemical libraries to identify novel lead series
against the kinetoplastid parasites, Leishmania dono-
vani (leishmaniasis) and Trypanosoma cruzi (Chagas’
disease).
SCREENING ASSAYS
A major consideration for DNDi when developing
its early discovery strategy has been the complexity
of target validation (Sams-Dodd, 2005) and sub-
sequent paucity of validated targets essential to the
parasite which would be amenable for the develop-
ment of assays allowing high-throughput screening
in the ﬁeld of neglected diseases (Wyatt et al. 2011).
Indeed little has so far translated into R&D break-
throughs despite huge expectations following the
publication of the complete ‘Tritryp’ (Leishmania
major, Trypanosoma brucei and T. cruzi) genome
sequences in 2005, revealing that each genome con-
tains 8300–12000 protein-coding genes, of which
around 6500 are common to all 3 genomes. It is fair to
say that only a limited number of targets reviewed
elsewhere (Renslo and McKerrow, 2006), mostly
related to T. brucei sub-species, have so far reached a
substantial level of biological characterization and
validation in spite of the rapid development of the
technologies and methodologies required for their
assessment (Frearson et al. 2007). As far as kineto-
plastid diseases are concerned, most of the drugs used
in the ﬁeld act via unclear or unknownmechanisms of
action (Castillo et al. 2010). From the target-based
assays implemented for screening purposes, few were
able to deliver progressable candidates (Frearson
et al. 2010) and none have led to new drugs or drug
candidates in clinical research. This is partly due to a
lack of translation from the target-based activity to
whole-cell assays or in vivo activities. This obser-
vation is unfortunately not new to the ﬁeld of anti-
infective drug discovery, with similar hopes raised
from the ﬁrst publication of the bacterial genome in
1995, which triggered pharmaceutical companies to
move back to antibacterial research and development
using genomics-derived, target-based strategies to
screen for new classes of drugs with novel modes
of action. Despite the evaluation of more than
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300 genes, together with 70 high-throughput screen-
ing campaigns at Glaxo SmithKline (GSK) over a
period of 7 years, there was a very modest yield. A
mere 16 campaigns were able to deliver hits and only
5 of these could be turned into leads (Payne et al.
2007). Lessons learnt from this, and other speciﬁc
analyses have dramatically inﬂuenced antibacterial
drug discovery strategies within pharmaceutical
companies over the last decade. GSK took the
strategic decision to rely as early as possible on
in vitro phenotypic assays and in vivo models to
characterize the biological activity of the molecules
under investigation, together with the use of HTS
whole-cell assays for screening. Similarly, Product
Development Partnerships involved in drug discov-
ery activities for malaria (MMV), tuberculosis (TB
Alliance) and kinetoplastids (DNDi) have opted for
medium- to high-throughput screening based on
whole-cell assays to evaluate compound libraries
accessed from their partners for hit identiﬁcation.
This cell-based screening approach has already been
successfully used to identify several novel clinical
candidates including thiazolidinones, spiroindolones
and diarylquinolines for the treatment of hepatitis C,
malaria and tuberculosis respectively, as recently
reviewed by Keller et al. (2011).
The intracellular amastigotes of L. donovani and
T. cruzi in the host cells of infected tissues are the
focus of drug discovery eﬀorts. Because of the relative
failure of target-based screening in anti-infective
drug discovery, since 2008 DNDi has strategically
invested in the development and validation of high-
content phenotypic screening assays against the
intracellular stages of these parasites, in partnership
with Institut Pasteur Korea and the University of
Dundee. These assays are based on imaging analysis
technology that speciﬁcally diﬀerentiates between
infected and non-infected cells via the spatial
localization and segmentation of speciﬁc descriptors
related to the host cell and the parasites. The
development of those high-content screening assays
against L. donovani (Siqueira-Neto et al. 2012) and
T. cruzi, in combination with an increased 384-well
throughput capacity against the extracellular Try-
panosoma brucei brucei at the Eskitis Institute for
Cell and Molecular Therapies, Griﬃth University
(Sykes and Avery, 2009), have enabled the screening
of medium (10000–50000) to large size (50000–
200000) commercial and proprietary libraries ac-
cessed byDNDi. To date, this screening platform has
allowed evaluation of more than one million com-
pounds, leading to the identiﬁcation of numerous
novel active series against all three kinetoplastids,
many of which have been, or are currently being,
progressed in the lead optimization phase. In
addition to a dramatic increase in screening through-
put against the intracellular amastigote form of the
pathogens, high-content assays are also more in-
formative and more speciﬁc than colorimetric or
ﬂuorimetric assays. As such, it is possible to
discriminate between activity resulting from speciﬁc
pathogen killing versus activity due to host cell
damage, or any sub-cellular event possibly indicative
of a speciﬁc mechanism of action. Such additional
image analysis information can be used immediately
after screening or archived in anticipation of any
subsequent complementary analysis.
SELECTION OF CHEMICAL LIBRARIES : DND I ’S
APPROACHES
The introduction of automated high-content screen-
ing has led to very signiﬁcant increases in screening
throughput of intracellular Leishmania spp. and T.
cruzi amastigotes over the last ﬁve years. Never-
theless, compared to the classic throughput achieved
in pharmaceutical companies, with a capacity for tens
of thousands of screening points per month, it can
still only be considered as a medium-throughput
screen. Therefore judicious selection and prioriti-
zation of chemical libraries is necessary to take
advantage of the still limited capacity.
DNDi collaborates closely with its industrial
partners, and has built new research partnerships
with a number of pharmaceutical and biotechnology
companies over the last 18 months in order to access
chemical diversity (Ioset and Chang, 2011). Not only
does this enable access to quality chemical libraries,
but also, very importantly, to well annotated ana-
logues after identiﬁcation of hits from primary
screens of small representative libraries. Most of our
research collaborations have come with initial restric-
tions on publication of structural data from primary
screens. Nonetheless, in line with DNDi’s policy of
open access, we are in positive negotiations with most
partners from the pharmaceutical industry to make
structures and annotation available as hits progress to
lead optimization programmes, following the DNDi
internally deﬁned criteria and proposed cut-oﬀ values
to qualify at the hit and lead selection stages (see
Tables 1 and 2). It is worth noting that these are not
applied strictly but are used to guide and prioritize
hit and lead series, with the global activities, toxicities
and chemical proﬁles being taken into account. The
criteria and values listed are reviewed on a regular
basis and are therefore subject to change.
Having gained access to considerable chemical
diversity from the pharmaceutical industry, it has
been necessary to carefully select or request speciﬁc
libraries. Complete ﬁles belonging to large pharma-
ceutical companies are in the order of several million
compounds and, as such, are still beyond the capacity
for screening against intracellular amastigotes. The
main strategies adopted by DNDi for library selec-
tion are outlined below.
Indication/repositioning libraries are small ﬁles of
a few hundred compounds which have progressed
to preclinical or clinical development for a variety
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of indications, with some compounds already re-
gistered as drugs. Screening such libraries could
be considered to be very much a lottery, where the
chance of success is very low but a positive hit would
be associated with considerable annotation associated
with a drug discovery programme. Unfortunately, no
promising hits have yet been identiﬁed from screens
of indication sets sponsored by DNDi.
A similar high-risk but potentially high-return
strategy has been the screening of libraries which
address speciﬁc pharmacokinetic, absorption, distri-
bution, metabolism and excretion (PK/ADME)
criteria. These include compounds which are orally
available or which cross the blood-brain barrier,
essential for drugs intended to treat human African
trypanosomiasis. It is expected that any active com-
pounds would qualify for, or be close to qualifying
for, in vivo eﬃcacy testing, and may also be related to
a well characterized family of compounds held by
the partner from the pharmaceutical sector. A small
number of hits have been identiﬁed in these screens.
In all cases, the human targets against which these
compounds were developed did not have an equiv-
alent parasitic target, and it is probable that the
mechanism of action in the parasite is diﬀerent.
Chemical classes with known anti-infective prop-
erties are the third class of compounds we selected
for screening. These have included macrolides,
ﬂuoroquinolones, oxazolidinones, hydrazones, ribo-
some inhibitors and anti-fungal compounds amongst
many other proprietary anti-infective compounds.
None have so far yielded hits which have progressed
past early lead optimization eﬀorts. This probably
reﬂects the absence or genotypic divergence of the
kinetoplastid target from that in the infectious agents
against which the original pharmaceutical research
was directed. This can be illustrated by the diﬀer-
ences in phylogenetic lineage and functional homo-
logy of DNA topoisomerase II from eukaryotic
kinetoplastids as compared to other eukaryotic cells
or prokaryotic bacteria, the latter being the target
of quinolone antibiotics (Das et al. 2004). It should
be noted, however, that this collaborative screening
approach has not been exhaustively completed
with the relevant pharmaceutical and biotechnology
companies.
DNDihas sponsored a small number of phenotypic
screens with target-based libraries such as protease
inhibitors and kinase inhibitors. In general they have
been avoidedbecause of a lackof a thoroughvalidation
of these targets in spite of the considerable eﬀorts
of drug discovery directed towards them during the
last few decades (Renslo and McKerrow, 2006;
McKerrow et al. 2008; Chawla and Madhubala,
2010). In addition, it is also likely that compounds
with speciﬁcity towards the human orthologues of
these targets will display reduced activity against the
parasite target. This potential issue could eventually
be addressed in the lead optimization phase in close
collaboration with a pharmaceutical company via a
selection of pre-existing moderately active or in-
active analogues against the human target, as well as
through the selective synthesis of analogues using in
silicomodelling tools supportedbyacounter screenon
a human kinase panel.
Finally, diversity libraries have been selected as
a source of new leads, such as the Pﬁzer Global
Diversity Research Set which consists of 150000
compounds representative of the global Pﬁzer
3·5 million collection (Bell et al. 2013). Several
additional core diversity sets have also been accessed
and screened by DNDi as part of ongoing collabor-
ations with pharmaceutical companies. DNDi ex-
pects to identify most of their new compound classes
for development from these and similar libraries,
althoughlowhit rates, lackofR&Dbackgroundknow-
ledge and IP encumbrance may present obstacles
along theway.Theglobalhit rateof so-calledunbiased
diversity sets is lower than 0·1% (ranging from 0·02 to
0·09%) when screening against the intra-macrophagic
Table 1. Criteria at hit stage
Criteria Parameter Hit HAT Hit VL Hit Chagas
Eﬃcacy in vitro Activity IC50410 μM
T. b. brucei
sub-species
bloodstream form
IC50410 μM
L. donovani or
L. infantum
intracellular
amastigote assay
IC50410 μM
T. cruzi intracellular
amastigote assay TcVI
(Tulahuen) or TcII/Y strain
Selectivity 10 fold more active vs mammalian cell line
DMPK in silico Lipinski’s rules Used to prioritize hits but should not be used as deﬁnitive selection criteria
(drug-likeness preferable but not essential)
Structural alerts
(metabolism/stability/
reactivity)
Proceed with caution and assay asap to determine extent of perceived problem
Toxicity in silico Structural alerts Proceed with caution and assay asap to determine extent of perceived problem
Chemical proﬁle Chemical tractability Acceptable synthetic pathway for compound and/or analogues (<8 steps)
Stereo-chemistry Assessed as part of chemical tractability
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Table 2. Criteria at lead stage
Criteria Parameter Lead HAT Lead VL Lead Chagas
Eﬃcacy in vitro Activity IC50 10–20-fold increase in
activity over Hit Active against
T. b. rhodesiense and/or
T. b. gambiense sub-species
IC5041 μM IC5041 μM
Active against a panel of
clinical isolates (Indian,
Soudanese) and
antimonial-resistant strain
IC50 10–20-fold increase in
activity over Hit
Selectivity Increased over Hit (ideally550-fold) more active vs. mammalian cell line
Eﬃcacy in vivo Signiﬁcant reduction in parasitaemia and/or
increase in life-span (4×50mg kg−1) i.p or
p.o in acute model
>70% reduction in
liver parasitaemia after
i.p administration
80% parasitaemia reduction
or no parasites detected at the
end of treatment and increase
in life-span (10×50mg kg−1 p.o.)
DMPK in silico Lipinski’s rules Used to prioritize hits but should not be used as deﬁnitive selection criteria (drug-likeness preferable but not essential)
DMPK in vitro Metabolic stability
(mouse and human (S9) liver
microsomes)
Stability – progress compounds ranked ‘medium’ or ‘high’ in assays (e.g. Clint <50mLmin−1 kg−1, t 1/2 >30min)
Caco 2 or MDCK Pgp
cell permeability
Progress compounds ranked ‘medium’
or ‘high’ in assays
Not required
Solubility Lowest value at pH 7.4>0.01mgmL−1
Protein binding Only measured if perceived problem with bioavailability
CYP3A4 inhibition IC50 >10 μM
Plasma and whole blood stability Measured
DMPK in vivo Mouse PK Plasma concentration in the range of active concentrations observed after
i.p administration
Mouse exposure at 10mg kg−1 bid
or 20mg k−1 qd. compounds which
achieve plasma levels above IC50 for at
least 24 h are progressed in vivo
Toxicity in vitro Presence of structural alerts Proceed with relevant assays (e.g. genotoxicity: AMES test, cardiotoxicity: hERG assay)
Toxicity in vivo Not overtly toxic in mice at the eﬃcacious dose
Chemical proﬁle Chemical tractability No potential liabilities which prevent scaled-up synthesis to 1g+
Structure-activity relationship
(SAR)
Preliminary SAR with minimum 10 compounds: avoid series lacking SAR or displaying ‘ﬂat’ SAR
Stereo-chemistry Establish contribution to activity/toxicity/metabolism, ideally no chiral centre
143
D
rug
developm
ent
to
treat
kinetoplastid
infections
https:/w
w
w
.cam
bridge.org/core/term
s. https://doi.org/10.1017/S003118201300142X
D
ow
nloaded from
 https:/w
w
w
.cam
bridge.org/core. U
niversity of B
asel Library, on 11 Jul 2017 at 09:56:37, subject to the C
am
bridge C
ore term
s of use, available at
form ofL. donovani, taking an activity cut-oﬀ of 10 μM
in dose-response determinations, calculated as IC50
combined with a 10-fold selectivity index versus
a mammalian cell line. This hit rate was obtained
from screening approximately 500000 compounds
from a variety of libraries, and is signiﬁcantly lower
than that from screening campaigns against the
bloodstream formofT. brucei (average 0·45%, ranging
from 0·1–1·2%, approximately 1·1 million com-
pounds assayed) as well as the intra-macrophagic
form of T. cruzi (average 0·30%, ranging from
0·05–0·85%, approximately 500000 compounds as-
sayed).The relativelywide data distribution related to
the assay hit rates can mostly be explained by the use
of various assay protocols and screening laboratories
to operate the screens as well as by the nature of the
compound collections submitted to these assays as
each library has been designed using a distinct set of
criteria.
Such a low hit rate for intracellular L. donovani
screening, compared to that of the extracellular blood
stream form of T. brucei sp., is not surprising. For a
compound to reach a target in an intracellular parasite
it must ﬁrst pass through two host cell membranes
and often hostile environments for a drug-like
compound, including a pH of 5·4 and a range of
cell host lysosomal enzymes in the parasitophorous
vacuole (Lang et al. 1994). Moreover, intracellular
amastigotes ofL. donovani are slow-replicating patho-
gens (De Rycker et al. 2013) compared to intra-
cellular amastigotes of T. cruzi, and have developed
very sophisticated strategies to survive using a
reduced metabolism within the host cell defence
system (Kima, 2007; Pescher et al. 2011). Also, by
hiding in the vacuolar compartment it is diﬃcult for
drugs to reach the parasites and exert their eﬀect on
biochemical pathways or targets that are still func-
tional and essential to the survival of the L. donovani
amastigote pathogen.
Not all hit compounds which come out of the
screening process continue through to lead optimiz-
ation: a signiﬁcant number are dropped following
analysis and careful assessment of the identiﬁed
molecules, due to chemical clustering, duplication
with ongoing and past hit-to-lead and lead optimiz-
ation programmes at DNDi or elsewhere, and incom-
patibility with the current internal target product
proﬁles deﬁned from those diseases (www.dndi.org/
diseases-projects/diseases.html). When the mechan-
ism of action is not known, nor any preliminary
structure-activity relationships associated with po-
tency, it is usually safer to rely on hits associated with
a high level of potency (ideally at the submicromolar
level) in a phenotypic assay. Hit-to-lead and lead
optimization experience has taught us that improving
potency in the complex environments found in
L. donovani or T. cruzi intracellular assays is a rather
challenging task. Instead, optimization of PK/
ADME is required to improve in vivo eﬃcacy and
build PK/PD knowledge within a speciﬁc series.
Despite these hurdles, phenotypic screening is still
considered more appropriate than target-based
screening, and the fastest way to increase chemical
diversity in a ﬁeld where most targets are not fully
validated and few known anti-infective classes of
compounds are potent. To date, DNDi has identiﬁed
an estimated total of over 50 chemical lead series from
its screening and post-screening operations, with
some, such as nitroimidazoles and oxaboroles, active
against multiple protozoans. Two drug candidates
emerging from this preclinical pipeline (www.dndi.
org/diseases-projects/portfolio.html) are currently
being progressed in clinical trials for human African
trypanosomiasis (fexinidazole and SCYX-7158) and
visceral leishmaniasis (fexinidazole).
FUTURE PERSPECTIVES
A large diversity within screened chemical libraries
is most likely to yield the greatest number of new
starting points for drug discovery. Currently, the
major hurdle to this strategy is the technical (coupled
to a ﬁnancial) limitation in the capacity to screen
against whole cell organisms, especially with respect
to intracellular protozoa. Innovative approaches
to improve throughput would relieve this bottleneck,
and are currently under investigation. A recent
manuscript (De Rycker et al. 2013) assessed the use
of free living L. donovani axenic amastigotes as
a surrogate predictive for intracellular amastigote
activity. This comparative study demonstrated that
from a screen of 16000 diverse compounds in both
axenic and intra-macrophage assays, with reconﬁr-
mation of the axenic hits in an intracellular assay, the
hits obtained from the intracellular screen were also
identiﬁed in the axenic amastigote screen. The axenic
pre-screen identiﬁed a large number of positives
that did not translate to the intracellular screen
(false positives) but reduced the size of the library
for conﬁrmatory screening by more than 95%. Thus,
a pre-screen against the extracellular form of the
L. donovani parasite, followed by reconﬁrmation of
the primary actives in the intracellular amastigote
form of the assay, could oﬀer a valuable cost-eﬀective
screening cascade when dealing with very large phar-
maceutical company libraries. Such an approach
could reasonably be applied to several global ﬁles
from pharmaceutical companies. Indeed, despite
diﬃculties in estimating the overlap in the chemical
diversity between collections from Big Pharma,
a recent precompetitive analysis of AstraZeneca
(2·5 million) and Bayer Pharma AG (1·4 million)
compound collections based on 2D near neighbour
molecular ﬁngerprinting highlighted only a limited
overlap between the 2 compound sets (Kogej et al.
2013).
Screening larger diversity sets in association with
an increasing capacity might not be the only way to
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secure new series for further development, however.
At DNDi we intend to investigate, validate and
eventually implement several alternative approaches
to capture additional active scaﬀolds through an im-
proved and more sophisticated selection of libraries.
One attractive research avenue that we are currently
exploring to signiﬁcantly enhance the hit rate of
screening programmes is the development of activity-
predictive models, using public and proprietary data
sets (the latter assumes partner’s approval to use its
IP in this framework has been secured). Such
models have already been recently applied in the
ﬁeld of anti-infective discovery, notably in an Open
Source context for tuberculosis and malaria (Periwal
and Kishtapuram, 2012; Jamal and Periwal, 2013).
Although is it still too early to come to any deﬁnite
conclusions regarding this innovative approach,
predictive modelling is expected to assist the prior-
itization of compounds to be submitted for screening
and drastically reduce the related screening expenses,
whilst increasing the hit rate and identiﬁcation of
novel active series.
The development of classiﬁcation techniques
to compare and visualize collections of compounds,
such as through a list of descriptors related or
unrelated to the chemical structure of the compound
sets using Principal Component Analysis (Feher and
Schmidt, 2003), without requesting the structural
information to be shared among parties, could also
be a valuable way to prioritize compound libraries for
screening when collaborating with multiple pharma-
ceutical companies. Such tools could be used to share
knowledge and identify potential opportunities to
combine eﬀorts at a later stage of drug development
(e.g. across Product Development Partnerships pre-
clinical programmes) without compromising conﬁ-
dentiality between the parties.
While obviously committed to honour any IP of its
collaborating parties, DNDi also aims to share any
derived knowledge with the scientiﬁc community
active in the ﬁeld of Neglected Diseases via its Open
Innovation portal (www.dndi.org/diseases-projects/
open-innovation.html). Just as GSK has previously
published the 13533 chemical libraries of com-
pounds active against Plasmodium falciparum result-
ing from the screening of its 2 million compound
library (Gamo et al. 2010), DNDi has also deposited
various data sets in the public domain, from screen-
ing and lead programmes. These include the screen-
ing of the Medicines for Malaria Venture (MMV)
malaria box (www.mmv.org/malariabox), an exciting
and innovative initiative to boost drug discovery
in the ﬁeld of neglected disease. More data will follow
as publication authorization is granted by the
collaborating parties.
Finally, the few tractable lead series which have
been identiﬁed to date should be fully exploited
by using them to conduct in silico screens against
diversity libraries from diﬀerent sources. DNDi is
working with a number of pharmaceutical companies
to develop strategies to conduct such screens against
their libraries with each using their own proprietary
screening algorithms and avoiding contamination of
their intellectual property. This should maximize the
diversity of scaﬀolds and annotation around a single
series identiﬁed from a phenotypic screen.
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